163554-55-0

Basic information

• Product Name: Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI);tert-Butyl (1-forMylcyclobutyl)carbaMate
• CAS NO: 163554-55-0
• Molecular Formula: C10H17NO3
• Molecular Weight: 199.24688
• Product Categories: N-BOC
• Mol File: 163554-55-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 299.1±19.0 °C(Predicted)
• Appearance: /
• Density: 1.07±0.1 g/cm3(Predicted)
• PKA: 10.76±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI)(163554-55-0)
• EPA Substance Registry System: Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI)(163554-55-0)

Safety Data

• Hazardous Substances Data: 163554-55-0(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound that is commonly used as a reagent in chemical reactions. It is a formylcyclobutyl derivative of carbamic acid with a 1,1-dimethylethyl ester group. Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is known for its ability to react with a wide range of other chemicals, making it useful in the synthesis of various organic compounds. It is important to handle this chemical with care, as it may pose health hazards if not used properly. Overall, Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is a versatile compound with many applications in organic chemistry.

Upstream product

• 120728-10-1 1-[(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid 
• 1232365-37-5 tert-butyl N-[1-[methoxy(methyl)carbamoyl]cyclobutyl]carbamate 
• 54450-84-9 ethyl hydrogen cyclobutane-1,1-dicarboxylate 
• 163554-54-9 ethyl 1-[(tert-butoxycarbonyl)amino]cyclobutanecarboxylate 
• 1142211-17-3 tert-butyl (1-(hydroxymethyl)cyclobutyl)carbamate 

Relevant articles and documents

Selective cathepsin s inhibition with MIV-247 attenuates mechanical allodynia and enhances the antiallodynic effects of gabapentin and pregabalin in a mouse model of neuropathic pain

Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models. The current study evaluated the effects when combining the selective cathepsin S inhibitor MIV-247 with gabapentin or pregabalin in a mouse model of neuropathic pain. Mice were rendered neuropathic by partial sciatic nerve ligation. MIV-247, gabapentin, or pregabalin were administered alone or in combination via oral gavage. Mechanical allodynia was assessed using von Frey hairs. Neurobehavioral side effects were evaluated by assessing beamwalking. MIV-247, gabapentin, and pregabalin concentrations in various tissueswere measured. Oral administration of MIV-247 (100-200 μmol/kg) dose-dependently attenuated mechanical allodynia by up to approximately 50%reversal when given as a single dose or when given twice daily for 5 days. No behavioral deficits were observed at any dose of MIV-247 tested. Gabapentin (58-350 μmol/kg) and pregabalin (63-377 μmol/kg) also inhibited mechanical allodynia with virtually complete reversal at the highest doses tested. The minimum effective dose of MIV-247 (100 μmol/kg) in combination with the minimum effective dose of pregabalin (75 μmol/kg) or gabapentin (146 μmol/kg) resulted in enhanced antiallodynic efficacy without augmenting side effects. A subeffective dose of MIV-247 (50 μmol/kg) in combination with a subeffective dose of pregabalin (38 μmol/kg) or gabapentin (73 μmol/kg) also resulted in substantial efficacy. Plasma levels of MIV-247, gabapentin, and pregabalin were similar when given in combination as to when given alone. Cathepsin S inhibition with MIV-247 exerts significant antiallodynic efficacy alone, and also enhances the effect of gabapentin and pregabalin without increasing side effects or inducing pharmacokinetic interactions.

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and Rs

NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS

Compounds of the formula (I) wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together wi